05:51 AM EDT, 08/13/2024 (MT Newswires) -- Calliditas Therapeutics ( CALT ) reported a Q2 loss Tuesday of 0.88 Swedish kronor ($0.084) per diluted share, narrower than a loss of 1.71 kronor a year earlier.

A single analyst polled by Capital IQ expected a profit of 0.50 kronor.

Revenue for the quarter ended June 30 was 559.8 million kronor, compared with 269.4 million kronor a year earlier.

Analysts surveyed by Capital IQ expected 459 million kronor.

Price: 38.70, Change: -0.48, Percent Change: -1.24